Neurophysiological experiments support the hypothesis of the presence of critical dynamics of brain activity. This is also manifested by power law of electroencephalography (EEG) power spectra, which can be described by the relation 1/f(alpha). This dependence is a result of internal interactions between parts of the brain and is probably required for optimal processing of information. In Alzheimer's disease, changes in the functional organization of the brain occur, which may be manifested by changes in the alpha coefficient. We compared the average values of alpha for 19 electrodes in the resting EEG record in 110 patients with moderate to severe Alzheimer's disease (Mini-Mental State Examination [MMSE] score = 10-19) with 110 healthy controls. Statistically, the most significant differences are present in the prefrontal areas. In addition to the prefrontal and frontal areas, the largest separation value in the evaluation of receiver operating characteristic (ROC) curves was recorded in the temporal area. The coefficient alpha has few false-positive results in the optimal operating point of the ROC curve, and is thereby highly specific for Alzheimer's disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1550059413491558 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Machine learning models for dementia screening to classify brain amyloid positivity on positron emission tomography using blood markers and demographic characteristics: a retrospective observational study.
Alzheimers Res Ther
January 2025
Department of Neurology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, Yufu, Oita, 879-5593, Japan.
Background: Intracerebral amyloid β (Aβ) accumulation is considered the initial observable event in the pathological process of Alzheimer's disease (AD). Efficient screening for amyloid pathology is critical for identifying patients for early treatment. This study developed machine learning models to classify positron emission tomography (PET) Aβ-positivity in participants with preclinical and prodromal AD using data accessible to primary care physicians.
View Article and Find Full Text PDFExploring the ability of plasma pTau217, pTau181 and beta-amyloid in mirroring cerebrospinal fluid biomarker profile of Mild Cognitive Impairment by the fully automated Lumipulse platform.
Fluids Barriers CNS
January 2025
Neurology 5 - Neuropathology Unit, Fondazione IRCCS - Istituto Neurologico Carlo Besta, Via Celoria 11, Milan, 20133, Italy.
Background: The approval of new disease-modifying therapies by the U.S. Food and Drug Administration and the European Medicine Agency makes it necessary to optimize non-invasive and cost-effective tools for the identification of subjects at-risk of developing Alzheimer's Disease (AD).
View Article and Find Full Text PDFUncovering cerebral blood flow patterns corresponding to Amyloid-beta accumulations in patients across the Alzheimer's disease continuum using the arterial spin labeling.
Neurol Sci
January 2025
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Background: Alzheimer's disease (AD) is a progressive neurodegenerative disorder ranging from mild cognitive impairment (MCI) to AD dementia. Abnormal cerebral perfusion alterations, influenced by amyloid-beta (Aβ) accumulations, have been implicated in cognitive decline along this spectrum.
Objective: This study investigates the relationship between cerebrospinal fluid (CSF) Aβ1-42 levels and regional cerebral blood flow (CBF) changes across the AD continuum using the Arterial Spin Labeling (ASL) technique.
Dual inhibition of AChE and MAO-B in Alzheimer's disease: machine learning approaches and model interpretations.
Mol Divers
January 2025
State Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian, 116024, Liaoning, China.
Alzheimer's disease (AD) is one of the most prevalent neurodegenerative diseases. Given the multifactorial pathophysiology of AD, monotargeted agents can only alleviate symptoms but not cure AD. Acetylcholinesterase (AChE) and Monoamine oxidase B (MAO-B) are two key targets in the treatment of AD, molecules that inhibiting both targets are considered promising avenue to develop more effective AD therapies.
View Article and Find Full Text PDFPsychotropic Polypharmacy in Dementia: A Retrospective Analysis for People with Neuropsychiatric Symptoms Referred to an Australian Dementia Support Service.
Drugs Aging
January 2025
The Dementia Centre, HammondCare, St Leonards, NSW, Australia.
Background And Objectives: Despite their limited benefits and serious adverse effects, psychotropics remain frequently prescribed for neuropsychiatric symptoms (NPS) of dementia. Psychotropic polypharmacy, the use of two or more concomitant psychotropic medications, is therefore not recommended for people with dementia. The objectives of this study were to investigate the prevalence of psychotropic polypharmacy in Australians living with dementia whose caregivers sought external NPS support from Dementia Support Australia (DSA; the national provider of NPS support) and the association of psychotropic polypharmacy with their demographics and NPS characteristics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!